Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).

Bengt Glimelius,Nebojsa Manojlovic,Per Pfeiffer,Baadur Mosidze,Galina Petrova Kurteva,Mia Karlberg,Devalingam Mahalingam,Marie Helene Bengtson,Jacques Näsström

Persistent prevention of CIPN using calmangafodipir (PledOx): Results from a placebo-controlled randomized phase II study (PLIANT) in patients with metastatic colorectal cancer (mCRC).

2016

Bengt Glimelius
Nebojsa Manojlovic
Per Pfeiffer
Baadur Mosidze
Galina Petrova Kurteva
Mia Karlberg
Devalingam Mahalingam
Marie Helene Bengtson
Jacques Näsström

10018Background: Chemotherapy-induced peripheral neuropathy (CIPN) is a major problem after oxaliplatin treatment. Calmangafodipir (CaM) has shown promising activities in model systems in preventin...

Keywords:

Placebo
Physical therapy
Oncology
Phases of clinical research
Calmangafodipir
Colorectal cancer
Internal medicine
Medicine
in patient
Peripheral neuropathy
Oxaliplatin

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations